Counting copy numbers characterises prostate cancer

Non-invasive 'liquid biopsies' can find metastatic or recurrent prostate cancer, in a low cost assay suitable for most healthcare systems, finds research published in BioMed Central's open access journal Genome Medicine. Genomic signatures of prostate cancer, isolated from plasma DNA, display abnormal copy numbers of specific areas of chromosomes. It is even possible to separate out patients who develop resistance against hormone deprivation therapy, which is the most common form of treatment in men with metastatic prostate cancer.

Prostate cancer is the most common cancer in men with 2.6 million new cases being diagnosed each year in Europe alone. PSA testing means that many cancers are found and treated at an early stage. However some men still have recurrent or metastatic disease despite treatment which appears to have destroyed the cancer.

Testing for metastasis remains a challenge requiring repeated biopsies. A team of researchers from the Medical University of Graz and the University Medical Center Hamburg Eppendorf investigated the possibility of testing for the presence of disease in a less invasive manner.

Using whole of plasma DNA, plus targeted sequencing of genes known to be involved in prostate cancer, the team discovered that there are abnormal copy numbers (some losses, some gains) of specific prostate cancer related sequences. Although this was a small scale study the presence of prostate cancer was flagged by copy number mistakes in sequences such as NCOA2, PHLPP1 and TMPRSS2-ERG. As expected each person's cancer signature was slightly different, however patients whose cancer did not respond to castration all had increased copy numbers of genes for the (AR).

Discussing the value of this research Dr Jochen Geigl and Prof Michael Speicher, who led this study commented, "The simplicity and low cost of 'liquid biopsies' make these genetic tests an attractive alternative to traditional biopsies. Better genetic information resulting from these tests may also help target treatment, especially of castration-resistant and aid personalised therapy in the clinic."

More information: Tumor associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing Ellen Heitzer, Peter Ulz, Jelena Belic, Stefan Gutschi, Franz Quehenberger, Katja Fischereder, Theresa Benezeder, Martina Auer, Carina Pischler, Sebastian Mannweiler, Martin Pichler, Florian Eisner, Martin Haeusler, Sabine Riethdorf, Klaus Pantel, Hellmut Samonigg, Gerald Hoefler, Herbert Augustin, Jochen B Geigl and Michael R Speicher Genome Medicine

add to favorites email to friend print save as pdf

Related Stories

Study identifies new prostate cancer drug target

Feb 06, 2012

Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

22 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.